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OBJECTIVE: Recent reviews of human memory processes in
cognitive psychology suggest that shorter recall periods in
patient-reported outcome (PRO) measures capture daily expe-
rience more accurately. Few empirical studies quantify patient
symptom reporting by length of the recall period. This study
compares 7-day recall of symptoms during the past week with
24-hour recall in a daily diary to determine whether the recall
period yields signiﬁcant differences in measures of patient
reported symptom occurrence and severity. METHODS: The
Cystic Fibrosis Respiratory Diary (CFRD) is a recently devel-
oped PRO including 13 symptoms (e.g. cough, tiredness, frus-
tration) in which patients record the occurrence and severity of
symptoms for six consecutive days using a 24-hour recall
period and on the seventh day using a 7-day recall period.
Cystic ﬁbrosis patients age 2 and older (parents for children age
11 or younger), completed two diaries while clinically stable
and one during a pulmonary exacerbation requiring medical
attention beyond their usual care. This analysis identiﬁes how
often patients’ 7-day recall of symptom occurrence (a
symptom-speciﬁc item with yes/no response) matches their six
day pattern of 24-hour recall (none/any), and compares 7-day
recall of symptom severity (4-category response scale, 0 to 3,
most severe is 3) to averaged daily 24-hour recall using a paired
t-test. RESULTS: A total of 1235 week-long symptom obser-
vations analyzed from 95 out of 145 diaries completed for all
seven days, represent 52 out of 56 participants. A total of
1,080/1235 (87%) of the 7-day recalls of symptom occurrence
matched the 6 day none/any pattern of daily 24-hour recall.
7-day recall of symptom severity (Mean, 0.42; SD, 0.77) was
greater than averaged daily 24-hour recall (Mean, 0.34; SD,
0.62) (p < 0.001). CONCLUSION: A 7-day recall period does
not produce the same results as daily 24-hour recall in a week-
long symptom diary.
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OBJECTIVE: The objective of this study was to assess reductions
in pain frequency and intensity in cervical dystonia patients
treated with botulinium toxin (BoNT-A). METHODS: A total of
170 patients were randomized to receive (BoNT-A) or placebo as
part of a 10-week, double-blind study. Patients assessed their
pain frequency on a scale from 0 (never) to 4 (constant) and their
pain intensity on a scale from 0 (none) to 4 (very severe). Pain
frequency and intensity were measured at follow-up visits at
weeks 2, 4, 6, 8, and 10. RESULTS: The mean baseline pain
frequency scores were 1.79 for the BoNT-A group and 1.91 for
the placebo group. The reduction in mean change of pain fre-
quency ranged from -0.19 to -0.37 in the BoNT-A group and
from -0.01 to -0.20 in the placebo group. A greater reduction in
the mean change in pain frequency was seen at all timepoints in
the botulinium toxin group; the difference was statistically sig-
niﬁcant at week 6 (-0.31 vs -0.01; P = 0.018). The mean baseline
pain intensity scores were 1.78 in the BoNT-A group and 1.80 in
the placebo group. The reduction in the mean change of pain
intensity ranged from -0.20 to -0.47 in the BoNT-A group, while
the placebo group had an increase in pain intensity at week 6, no
change from baseline at week 10, and reductions ranging from
-0.06 to -0.18 at other timepoints. The mean change in pain
intensity showed a greater reduction at all timepoints in the
BoNT-A group compared to placebo, with the difference being
statistically signiﬁcant at week 2 (-0.39 vs -0.07; P = 0.026) and
week 6 (-0.36 vs 0.06; P  0.001). Adverse events rates were
nearly equivalent between groups (59.1% BoNT-A vs. 58.5%
placebo group). CONCLUSION: Treatment with BoNT-A
lowered frequency and intensity of patient-assessed pain as com-
pared to placebo.
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OBJECTIVE: Patient reported outcomes (PROs) play an increas-
ingly important role in pharmaceutical clinical trials. The Food
and Drug Administration (FDA) recognizes that interviewer
training affects PRO study results. Further, the FDA asserts that
implementation of standardized interviewer training can opti-
mize study quality by minimizing inconsistencies in trial conduct.
Presently, there is no standard PRO interviewer training method,
and many registration trials neglect this important aspect of
ensuring quality data. To test the effectiveness of such training,
United BioSource Corporation (UBC) analyzed outcomes of PRO
interviewer training in a global clinical trial. METHODS: United
BioSource Corporation worked in conjunction with a pharma-
ceutical sponsor to develop a training program for an interviewer
administered PRO designed to assess symptom severity and
resultant distress to patients. Custom training on instrument
content, format and administration guidelines was provided to
519 potential interviewers live (70%) at 4 separate investigator
meetings (Nashville, Geneva, Kuala Lumpur, Buenos Aires), or
via the internet for those unable to attend an IM (30%). Follow-
ing training, interviewer knowledge was independently assessed
using an exam speciﬁcally created for that purpose. RESULTS: A
total of 519 interviewers completed the training. Seventy-four
percent of interviewers had no previous instrument speciﬁc expe-
rience. A total of 506 (97.5%) demonstrated scale knowledge
mastery (80% or greater). As shown by one-way ANOVAs,
performance was not affected by nationality, clinical experience,
clinical trials experience, or prior experience with the instrument
(all F ratios <1). CONCLUSION: We report the global delivery
of a comprehensive PRO interviewer training package consistent
with FDA goals. The study suggests that comprehensive PRO
interviewer training is feasible in multinational trials, is effective
in live or remote delivery platforms, and results in high levels of
demonstrable scale knowledge across a wide range of clinical and
research experience levels.
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OBJECTIVE: The objective of this analysis was to evaluate func-
tional disability in patients with cervical dystonia. METHODS:
The study consisted of a 10-week, non-randomized, open-label
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